Doppler announced today that Mr. Stavros Stavropoulos transferred to "SMERemediumCap" through an OTC transaction on June 14, 2024, 3.710.004 shares and the corresponding voting rights held in the company, representing 35% of the total share capital and voting rights of the company.

As a result of the aforementioned transfer, there was a change in the shareholdings and voting rights of the above shareholders in the company as of June 14, 2024, as follows:

1. Mr. Stavros Stavropoulos holds 2,754,753 shares and voting rights in the company, corresponding to 25.99% of the total shares and voting rights in the company, and has reached the threshold of 33.3%.

2. "SMERemediumCap" holds 3,710,004 shares and voting rights in the company, representing 35% of the total shares and voting rights in the company, and exceeded the 33.3% threshold. 

ANNOUNCEMENT IN FULL

In detail, the company states the following: 

Doppler announces to the investing public the information received on June 14, 2024, from its shareholders, Mr. Stavros Stavropoulos and "SMERemediumCap," in accordance with the provisions of Athens Exchange Alternative Market Regulation No. 14, regarding their participation and voting rights in the company.

On June 14, 2024, Mr. Stavros Stavropoulos transferred 3,710,004 shares and the associated voting rights that he had in the company to "SMERemediumCap" through an over-the-counter (OTC) transaction. This represented 35% of the company's total share capital and voting rights as of May 31, 2024, the date on which the general meeting of the company's shareholders decided to increase the share capital.

As a result of the aforementioned transfer, there was a change in the shareholdings and voting rights of the above shareholders in the company as of June 14, 2024, as follows: 

1. Mr. Stavros Stavropoulos holds 2,754,753 shares and voting rights in the company, corresponding to 25.99% of the total shares and voting rights in the company, and has reached the threshold of 33.3%. Furthermore, it is clarified, according to the information received by the Company from its shareholders, that in the context of the above transfer, an initial price of €0.23 per share was paid to Mr. Stavros Stavropoulos and there is an additional price of €450,000 in total, which "SMERemediumCap" is obliged to pay to Mr. Stavropoulos under certain conditions, according to the transaction documents, in three years from the date of the transaction. If the additional consideration is paid, the redemption price of the above shares will be €0.35 per share.

2. "SMERemediumCap" holds 3,710,004 shares and voting rights in the Company, representing 35% of the total shares and voting rights in the Company and exceeding the 33.3% threshold.

Furthermore, the Company announces that the shareholders, Mr. Stavros Stavropoulos, Ms. Athanasia Stavropoulou and Ms. Anthoula Stavropoulou, are, as of June 14, 2024, in a state of concerted behaviour and coordination with each other on all their shares of the Company's issue owned by the parties, i.e., 3,657.980 in total common, registered shares, after the voting rights attributable to them, corresponding to 34.51% of the total share capital and voting rights of the Company (as they were before the completion of the share capital increase resolved by the Ordinary General Meeting of the Company's shareholders on May 31, 2024), which are divided among them as follows: 

(a) Stavros Stavropoulos, 2,754,753 common registered shares after the proportional voting rights corresponding to them, corresponding to 25.99% 

(b) Athanasia Stavropoulou: 694,301 common nominal shares after the proportional voting rights corresponding to 6.55% and

(c) Anthoula Stavropoulou has 208,926 common nominal shares after the proportional voting rights corresponding to 1.97%.